These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 34020912)

  • 1. Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy.
    Yang WH; Qiu Y; Stamatatos O; Janowitz T; Lukey MJ
    Trends Cancer; 2021 Aug; 7(8):790-804. PubMed ID: 34020912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
    Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
    J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamine Metabolism Heterogeneity in Glioblastoma Unveils an Innovative Combination Therapy Strategy.
    Fu H; Wu S; Shen H; Luo K; Huang Z; Lu N; Li Y; Lan Q; Xian Y
    J Mol Neurosci; 2024 May; 74(2):52. PubMed ID: 38724832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
    Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
    BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging.
    Abu Aboud O; Habib SL; Trott J; Stewart B; Liang S; Chaudhari AJ; Sutcliffe J; Weiss RH
    Cancer Res; 2017 Dec; 77(23):6746-6758. PubMed ID: 29021138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
    Reis LMD; Adamoski D; Ornitz Oliveira Souza R; Rodrigues Ascenção CF; Sousa de Oliveira KR; Corrêa-da-Silva F; Malta de Sá Patroni F; Meira Dias M; Consonni SR; Mendes de Moraes-Vieira PM; Silber AM; Dias SMG
    J Biol Chem; 2019 Jun; 294(24):9342-9357. PubMed ID: 31040181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
    Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
    Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
    Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting glutamine metabolism slows soft tissue sarcoma growth.
    Lee P; Malik D; Perkons N; Huangyang P; Khare S; Rhoades S; Gong YY; Burrows M; Finan JM; Nissim I; Gade TPF; Weljie AM; Simon MC
    Nat Commun; 2020 Jan; 11(1):498. PubMed ID: 31980651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
    Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
    Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acidosis-induced metabolic reprogramming in tumor cells enhances the anti-proliferative activity of the PDK inhibitor dichloroacetate.
    Schoonjans CA; Joudiou N; Brusa D; Corbet C; Feron O; Gallez B
    Cancer Lett; 2020 Feb; 470():18-28. PubMed ID: 31812695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting GLS1 to cancer therapy through glutamine metabolism.
    Yu W; Yang X; Zhang Q; Sun L; Yuan S; Xin Y
    Clin Transl Oncol; 2021 Nov; 23(11):2253-2268. PubMed ID: 34023970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
    Thompson RM; Dytfeld D; Reyes L; Robinson RM; Smith B; Manevich Y; Jakubowiak A; Komarnicki M; Przybylowicz-Chalecka A; Szczepaniak T; Mitra AK; Van Ness BG; Luczak M; Dolloff NG
    Oncotarget; 2017 May; 8(22):35863-35876. PubMed ID: 28415782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.
    Chen Y; Zhao Y; Bajor DL; Wang Z; Selfridge JE
    J Genet Genomics; 2020 Jul; 47(7):389-395. PubMed ID: 33004309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of anti-tumor effect and mechanism of GLS1 inhibitor CB-839 in colorectal cancer using a stroma-abundant tumor model.
    Miyamoto R; Takigawa H; Yuge R; Shimizu D; Ariyoshi M; Otani R; Tsuboi A; Tanaka H; Yamashita K; Hiyama Y; Urabe Y; Ishikawa A; Sentani K; Oka S
    Exp Mol Pathol; 2024 Jun; 137():104896. PubMed ID: 38703552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
    Elgogary A; Xu Q; Poore B; Alt J; Zimmermann SC; Zhao L; Fu J; Chen B; Xia S; Liu Y; Neisser M; Nguyen C; Lee R; Park JK; Reyes J; Hartung T; Rojas C; Rais R; Tsukamoto T; Semenza GL; Hanes J; Slusher BS; Le A
    Proc Natl Acad Sci U S A; 2016 Sep; 113(36):E5328-36. PubMed ID: 27559084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
    Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
    Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice.
    Boysen G; Jamshidi-Parsian A; Davis MA; Siegel ER; Simecka CM; Kore RA; Dings RPM; Griffin RJ
    Int J Radiat Biol; 2019 Apr; 95(4):436-442. PubMed ID: 30557074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
    Gregory MA; Nemkov T; Reisz JA; Zaberezhnyy V; Hansen KC; D'Alessandro A; DeGregori J
    Exp Hematol; 2018 Feb; 58():52-58. PubMed ID: 28947392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
    Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
    PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.